Monitor for future reimbursement updates or revenue disclosures from the CNSide diagnostic platform, as this agreement adds coverage but no financial terms were provided. The name change to Cerenome and ticker change to CNSY on August 3 is administrative but may create short-term ticker confusion.
Price Chart
Executive Summary
Plus Therapeutics subsidiary CNSide Diagnostics signed a regional agreement with Medical Mutual covering ~1.2M members in Ohio and Kentucky, expanding total CNSide CSF TCE assay contracted coverage to ~127M people. The press release also announces a corporate name change to Cerenome, Inc. and ticker change to CNSY effective August 3, 2026. This is a modest commercial expansion for a diagnostic test with no disclosed financial terms, and the name change is administrative — overall impact is limited for a $26M market cap company.
Key Facts
- CNSide Diagnostics signed a regional agreement with Medical Mutual effective July 1, 2026, covering ~1.2M people in Ohio and Kentucky.
- Total CNSide CSF TCE assay contracted coverage now ~127M people.
- More than 11,000 CNSide tests performed at 120+ U.S. cancer institutions since 2020.
- CNSide test has 92% sensitivity and 95% specificity, influencing treatment decisions in 90% of cases.
- Plus Therapeutics will change corporate name to Cerenome, Inc. and ticker to CNSY effective August 3, 2026.
Financial Impact
No financial terms disclosed; agreement covers ~1.2M additional lives, bringing total contracted coverage to ~127M.
Risk Factors
- No financial terms disclosed — revenue impact from this agreement is unquantifiable.
- Diagnostic test revenue may be modest relative to clinical-stage therapeutic pipeline costs.
- Name change and ticker change could cause temporary trading confusion or liquidity issues.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3330332 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 21, 2026 14w ago | Press Release | $3.92 | awaiting T+20 | — | — |
Jun 30, 2026 17w ago | Press Release | $4.37 $3.73 | ▼ −14.65% | ▼ −13.62% | — |
Jun 8, 2026 20w ago | EFFECT | $5.53 $4.05 | ▲ +26.76% | ▲ +28.39% | — |
Jun 5, 2026 20w ago | S-3/A | $5.41 $4.05 | ▼ −25.14% | ▼ −27.00% | — |
May 19, 2026 23w ago | Press Release | $5.83 $4.31 | ▼ −26.07% | ▼ −27.06% | — |
May 15, 2026 23w ago | Press Release | $5.84 $4.57 | ▲ +21.75% | ▲ +23.33% | — |
May 8, 2026 24w ago | Press Release | $6.12 $5.41 | ▼ −11.60% | ▼ −11.62% | — |
Apr 28, 2026 26w ago | Press Release | $5.95 $6.60 | ▲ +10.92% | ▲ +5.46% | — |
Apr 21, 2026 27w ago | 8-K | $7.14 $5.84 | ▼ −18.21% | ▼ −23.12% | — |
Apr 9, 2026 28w ago | 8-K | $3.92 $6.00 | ▲ +53.06% | ▲ +45.49% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers